Current Cancer Drug Targets

Papers
(The H4-Index of Current Cancer Drug Targets is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
The Expression of Glutaminases and their Association with Clinicopathological Parameters in the Head and Neck Cancers85
Combined RNAi of CTTN and FGF2 Modulates Cell Migration, Invasion and G1/S Transition of Hepatocellular Carcinoma through Ras/ERK Signaling Pathway43
Spinal KCC2 Mediates the Modulation Effect of HDAC2 on Bone Cancer Pain in Rats40
Micro-fragmented Fat Inhibits the Progression of Human Mesothelioma Xenografts in Mice34
A Pilot Study of Anlotinib as a Combination Treatment in Advanced Nasopharyngeal Carcinoma30
Unveiling Novel Therapeutic Drug Targets and Prognostic Markers of Triple Negative Breast Cancer26
Silencing HEATR1 Rescues Cisplatin Resistance of Non-small Cell Lung Cancer by Inducing Ferroptosis via the p53/SAT1/ALOX15 Axis25
Development of Chromatin Regulator-related Molecular Subtypes and a Signature to Predict Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma24
Expression, Prognostic Value, and Immune Infiltration of MTHFD Family in Bladder Cancer24
Knockdown of PRKD2 Enhances Chemotherapy Sensitivity in Cervical Cancer via the TP53/CDKN1A Pathway23
Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer22
The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention22
Bioinformatics and Experimental Study Revealed LINC00982/ miR-183-5p/ABCA8 Axis Suppresses LUAD Progression16
TBOPP, a DOCK1 Inhibitor, Potentiates Cisplatin Efficacy in Breast Cancer by Regulating Twist-mediated EMT15
Progress in Metabolic Studies of Gastric Cancer and Therapeutic Implications14
Etiology-based Molecular Characterization of Hepatocellular Carcinoma Reveals SQLE’s Contribution to Immunosuppressive Microenvironment14
LMNB1/CDKN1A Signaling Regulates the Cell Cycle and Promotes Hepatocellular Carcinoma Progression14
0.037141084671021